Spero Therapeutics (SPRO) Given Daily Coverage Optimism Rating of 0.07
Media coverage about Spero Therapeutics (NASDAQ:SPRO) has trended somewhat positive this week, according to Accern. The research group identifies positive and negative media coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Spero Therapeutics earned a news impact score of 0.07 on Accern’s scale. Accern also gave news headlines about the company an impact score of 46.8560845318302 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Shares of Spero Therapeutics (NASDAQ:SPRO) traded up $0.16 during trading hours on Monday, reaching $13.86. The company’s stock had a trading volume of 13,200 shares, compared to its average volume of 87,110. Spero Therapeutics has a 1-year low of $10.83 and a 1-year high of $15.40.
SPRO has been the subject of a number of research analyst reports. Bank of America Corporation initiated coverage on Spero Therapeutics in a research note on Monday. They issued a “neutral” rating for the company. Stifel Nicolaus initiated coverage on Spero Therapeutics in a research note on Monday. They set a “buy” rating and a $26.00 price objective for the company. Cowen Inc initiated coverage on Spero Therapeutics in a research note on Monday. They set an “outperform” rating for the company. Finally, Oppenheimer Holdings, Inc. initiated coverage on Spero Therapeutics in a research note on Monday. They set a “buy” rating and a $30.00 price objective for the company.
In related news, CFO Joel Sendek acquired 5,000 shares of the stock in a transaction on Monday, November 6th. The stock was acquired at an average price of $14.00 per share, for a total transaction of $70,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Plc Glaxosmithkline acquired 428,571 shares of the stock in a transaction on Monday, November 6th. The shares were bought at an average price of $14.00 per share, with a total value of $5,999,994.00. The disclosure for this purchase can be found here. Insiders have acquired 649,356 shares of company stock valued at $9,090,984 in the last quarter. 13.90% of the stock is owned by company insiders.
COPYRIGHT VIOLATION NOTICE: “Spero Therapeutics (SPRO) Given Daily Coverage Optimism Rating of 0.07” was reported by Watch List News and is owned by of Watch List News. If you are reading this piece on another publication, it was illegally copied and republished in violation of US & international trademark and copyright laws. The original version of this piece can be read at https://www.watchlistnews.com/spero-therapeutics-spro-given-daily-coverage-optimism-rating-of-0-07/1729126.html.
Spero Therapeutics Company Profile
SmartPros Ltd. is engaged in provision of learning and educational solutions in content areas that target specific markets, including accounting/finance, legal, engineering, securities and insurance. The Company also provides education in banking, finance, taxation, information technology, health and safety, human resources and compliance for the general corporate market.
Receive News & Ratings for Spero Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.